UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 213

Sortiert nach

Founder effect is responsible for the p.Leu131Phe heparin‐binding‐site antithrombin mutation common in Hungary: phenotype analysis in a large cohort

Journal of thrombosis and haemostasis, 2016-04, Vol.14 (4), p.704-715

2016

Volltextzugriff (PDF)

Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants

British journal of anaesthesia : BJA, 2018-04, Vol.120 (4), p.645-656

2018

Volltextzugriff (PDF)

The use of recombinant factor XIII in a major bleeding episode of a patient with congenital factor XIII deficiency - the first experience

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-01, Vol.21 (1), p.e118-e121

2015

Volltextzugriff (PDF)

C0290: Diagnostic Considerations Based on the Experience of Genetic Analysis in Protein S Deficiency in the Hungarian Population with High Frequency of FV Leiden Mutation

Thrombosis research, 2014-05, Vol.133, p.S81-S81

2014

Volltextzugriff (PDF)

C0384: High Prevalence of Antithrombin Budapest 3 Mutation in Hungary, Investigation of Founder Effect

Thrombosis research, 2014-05, Vol.133, p.S11-S12

2014

Volltextzugriff (PDF)

Accelerated clearance alone explains ultra‐large multimers in von Willebrand disease Vicenza

Journal of thrombosis and haemostasis, 2010-06, Vol.8 (6), p.1273-1280

2010

Volltextzugriff (PDF)

Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population

Journal of thrombosis and haemostasis, 2011-05, Vol.9 (5), p.945-952

2011

Volltextzugriff (PDF)

Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs

The New England journal of medicine, 2010-09, Vol.363 (13), p.1222-1232

2010

Volltextzugriff (PDF)

A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management

Journal of thrombosis and haemostasis, 2012-03, Vol.10 (3), p.359-367

2012

Volltextzugriff (PDF)

Anti‐factor V auto‐antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding

Journal of thrombosis and haemostasis, 2003-05, Vol.1 (5), p.943-949

2003

Volltextzugriff (PDF)

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Thrombosis and haemostasis, 2017, Vol.117 (2), p.252

2017

Volltextzugriff (PDF)

P052 Low dose factor concentrate prophylaxis in patients with severe haemorrhagic disorders

Blood reviews, 2007, Vol.21, p.S102-S102

2007

Volltextzugriff (PDF)

P050 Successful immune tolerance induction treatment of therapy-resistent acquired haemophilia with high inhibitor titer: a case report

Blood reviews, 2007, Vol.21, p.S102-S102

2007

Volltextzugriff (PDF)

P049 Could heparin-induced thrombocytopenia and thrombosis be a rare manifestation of antiphospholipid antibody syndrome?

Blood reviews, 2007, Vol.21, p.S101-S102

2007

Volltextzugriff (PDF)

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

Journal of thrombosis and haemostasis, 2014-08, Vol.12 (8), p.1244-1253

2014

Volltextzugriff (PDF)

P018 Autologous bone marrow-derived stem cell transplantation in severe peripheral arterial disorder: the first five patients in Hungary

Blood reviews, 2007, Vol.21, p.S91-S92

2007

Volltextzugriff (PDF)

O26 A pilot study with autologous bone marrow-derived stem cell transplantation (ABSCT) in patients with severe peripheral arterial disorder (SPAD)

Blood reviews, 2007, Vol.21, p.S75-S75

2007

Volltextzugriff (PDF)

Platelet factor XIII becomes active without the release of activation peptide during platelet activation

Thrombosis and haemostasis, 1993, Vol.69 (3), p.282

1993

Volltextzugriff (PDF)

P061 Type 3 von Willebrand disease in Hungary: A partial large deletion is the most common genetic defect

Blood reviews, 2007, Vol.21, p.S105-S105

2007

Volltextzugriff (PDF)

High prevalence of factor V Leiden mutation and 20210A prothrombin variant in Hungary

Thrombosis and haemostasis, 1999-04, Vol.81 (4), p.660

1999

Volltextzugriff (PDF)

Safety of low-molecular-weight heparin in pregnancy: a systematic review

Thrombosis and haemostasis, 1999-05, Vol.81 (5), p.668

1999

Volltextzugriff (PDF)

Studies of the platelet filter test (shear dependent platelet aggregation) in patients with uncommon haemorrhagic disorders

Blood coagulation & fibrinolysis, 1996-03, Vol.7 (2), p.162-164

1996

Volltextzugriff (PDF)

Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy

Thrombosis and haemostasis, 1996, Vol.76 (1), p.128

1996

Volltextzugriff (PDF)

Use of a platelet filter test in patients with thrombocytosis

Platelets (Edinburgh), 2000, Vol.11 (1), p.38-42

Rejto, A. Schlammadinger, P. Laszlo, A. Kiss, B. Telek, Z. Boda, L.

2000

Volltextzugriff (PDF)

Three novel mutations in the glycoprotein IIb gene in a patient with type II Glanzmann thrombasthenia

Haematologica (Roma), 2007-05, Vol.92 (5), p.698-701

2007

Volltextzugriff (PDF)

1 – 25 von 213

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(186)
Mit Volltextzugriff
(129)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Founder effect is responsible for the p.Leu131Phe heparin‐binding‐site antithrombin mutation common in Hungary: phenotype analysis in a large cohort

Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants

The use of recombinant factor XIII in a major bleeding episode of a patient with congenital factor XIII deficiency - the first experience

C0290: Diagnostic Considerations Based on the Experience of Genetic Analysis in Protein S Deficiency in the Hungarian Population with High Frequency of FV Leiden Mutation

C0384: High Prevalence of Antithrombin Budapest 3 Mutation in Hungary, Investigation of Founder Effect

Accelerated clearance alone explains ultra‐large multimers in von Willebrand disease Vicenza

Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population

Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs

A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management

Anti‐factor V auto‐antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

P052 Low dose factor concentrate prophylaxis in patients with severe haemorrhagic disorders

P050 Successful immune tolerance induction treatment of therapy-resistent acquired haemophilia with high inhibitor titer: a case report

P049 Could heparin-induced thrombocytopenia and thrombosis be a rare manifestation of antiphospholipid antibody syndrome?

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

P018 Autologous bone marrow-derived stem cell transplantation in severe peripheral arterial disorder: the first five patients in Hungary

O26 A pilot study with autologous bone marrow-derived stem cell transplantation (ABSCT) in patients with severe peripheral arterial disorder (SPAD)

Platelet factor XIII becomes active without the release of activation peptide during platelet activation

P061 Type 3 von Willebrand disease in Hungary: A partial large deletion is the most common genetic defect

High prevalence of factor V Leiden mutation and 20210A prothrombin variant in Hungary

Safety of low-molecular-weight heparin in pregnancy: a systematic review

Studies of the platelet filter test (shear dependent platelet aggregation) in patients with uncommon haemorrhagic disorders

Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy

Use of a platelet filter test in patients with thrombocytosis

Three novel mutations in the glycoprotein IIb gene in a patient with type II Glanzmann thrombasthenia

Suchergebnisse filtern